KNAW

Publication

Effect of enzyme therapy in juvenile patients with Pompe disease: a... (2010)

Pagina-navigatie:
Title Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.
Published in Neuromuscular Disorders, Vol. 20, p.775-782. ISSN 0960-8966.
Author Capelle, C.I. van; Beek, N.A. van der; Hagemans, M.L.; Arts, W.F.M.; Hop, W.C.J.; Lee, P.; Jaeken, J.; Frohn-Mulder, I.M.; Merkus, P.J.F.M.; Corzo, D.; Puga, A.C.; Reuser, A.J.J.; Ploeg, A.T. van der
Date 2010
Type Article
Abstract Pompe disease is a rare neuromuscular disorder caused by deficiency of acid alpha-glucosidase. Treatment with recombinant human alpha-glucosidase recently received marketing approval based on prolonged survival of affected infants. The current open-label study was performed to evaluate the response in older children (age 5.9-15.2 years). The five patients that we studied had limb-girdle muscle weakness and three of them also had decreased pulmonary function in upright and supine position. They received 20-mg/kg recombinant human alpha-glucosidase every two weeks over a 3-year period. No infusion-associated reactions were observed. Pulmonary function remained stable (n = 4) or improved slightly (n = 1). Muscle strength increased. Only one patient approached the normal range. Patients obtained higher scores on the Quick Motor Function Test. None of the patients deteriorated. Follow-up data of two unmatched historical cohorts of adults and children with Pompe disease were used for comparison. They showed an average decline in pulmonary function of 1.6% and 5% per year. Data on muscle strength and function of untreated children were not available. Further studies are required.
Publication http://repository.ubn.ru.nl/handle/2066/88739
OpenURL Search this publication in (your) library
Persistent Identifier urn:nbn:nl:ui:22-2066/88739
Metadata XML
Repository Radboud University Nijmegen

Go to page top
Go back to contents
Go back to site navigation